Intellia Therapeutics Updates on Nex-Z Clinical Hold Following Patient Death in Phase 3 ATTR Trial
NTLA sits 80% above its 52-week low of $5.9.
Summary
Intellia Therapeutics provided an update on the clinical hold for its nexiguran ziclumeran (nex-z) Phase 3 trials, following a patient death and Grade 4 liver transaminase elevations, while also highlighting progress in its Lonvo-z program.
Key Events · Product Development and Regulatory · NTLA
-
Clinical Hold on Nex-z Trials
The FDA placed a clinical hold on the Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nexiguran ziclumeran (nex-z) due to safety concerns.
-
Patient Death Reported
A patient in the MAGNITUDE trial, who experienced Grade 4 liver transaminase elevations, subsequently died from septic shock secondary to a perforated duodenal ulcer.
-
Safety Event Context
Grade 4 liver transaminase elevations were reported in less than one percent of MAGNITUDE patients, with most resolving without sequelae, but the patient death is a serious adverse event.
-
Regulatory Path Forward
Intellia Therapeutics is working with regulators to finalize a plan for the nex-z program.
Analysis · NTLA · Life Sciences
The 8-K filing details the ongoing clinical hold on Intellia's pivotal Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nexiguran ziclumeran (nex-z), a gene-editing therapy for ATTR amyloidosis. This hold was initiated after a patient experienced Grade 4 liver transaminase elevations and subsequently died due to septic shock secondary to a perforated duodenal ulcer, following a complicated clinical course that included acute liver injury. While the company notes that Grade 4 liver transaminase elevations occurred in less than one percent of patients and resolved in most cases, the clinical hold on a late-stage program represents a significant setback, introducing uncertainty and potential delays for a key pipeline asset. Investors will closely monitor the company's discussions with regulators for a clear path forward. The filing also included a corporate presentation that provided positive updates on the Lonvo-z program for hereditary angioedema, which is progressing towards a BLA submission in the second half of 2026.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTLA was trading at $10.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.90 to $28.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.